# Study to Evaluate the Safety and Efficacy of CJ-30061 in Hypertensive Patients With Hyperlipidemia

Study · id `cardio:ct-nct03639480` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03639480](<https://clinicaltrials.gov/study/NCT03639480>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03639480

Browse, organ or system: Blood vessels; Metabolism  
Browse, condition area: Risk and prevention; High blood pressure; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 180 participants.

## Technical summary

Registry record NCT03639480. Randomized; quadruple masking; primary purpose treatment. Start 2017-10-13 (actual); primary completion 2018-10 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 180 participants (planned count; ClinicalTrials.gov record NCT03639480, source copy `cardio:ctgov-nct03639480-2018-08-21`, retrieved 2026-10-26)
- Started: 2017-10-13 (actual) (ClinicalTrials.gov record NCT03639480, source copy `cardio:ctgov-nct03639480-2018-08-21`, retrieved 2026-10-26)
- Primary completion: 2018-10 (anticipated) (ClinicalTrials.gov record NCT03639480, source copy `cardio:ctgov-nct03639480-2018-08-21`, retrieved 2026-10-26)
- Completion: 2018-10 (anticipated) (ClinicalTrials.gov record NCT03639480, source copy `cardio:ctgov-nct03639480-2018-08-21`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT03639480, source copy `cardio:ctgov-nct03639480-2018-08-21`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03639480-2018-08-21`, retrieved 2026-10-26)

## The registry's words

- Brief title: Study to Evaluate the Safety and Efficacy of CJ-30061 in Hypertensive Patients With Hyperlipidemia
- Condition: Hypertension
- Condition: Hyperlipidemia
- Intervention (Drug): Amlodipine 10mg+Valsartan 160mg+Atorvastatin 40mg
- Intervention (Drug): Amlodipine 10mg+Valsartan 160mg
- Intervention (Drug): Valsartan 160mg+Atorvastatin 40mg
- Lead sponsor: HK inno.N Corporation
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: HK inno.N Corporation (`cardio:org-hk-inno-n-corporation`)

## Provenance

Content hash: 4ddb6af9f463483e44e7cce7799d21ad62d9abf0637ebf4b621af18585b4fa84
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
